worse outcome, but you cant determine which

Preliminary experience shows that patients with chronic arthritis treated with bDMARDs or tsDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population.

Ref: https://ard.bmj.com/content/79/5/667

Dear Foad Alzoughool, thanks for your contribution.

COVID-19 has a high case-fatality rate (CFR) in transplant patients, particularly in those with long-term immunosuppressive regimens.

Article SARS-CoV-2 infection among patients with systemic autoimmune diseases

The following study reveals a higher mortality rate of COVID‐19 infection amongst hospitalized patients taking immunosuppressants.

Article Clinical characteristics and outcomes of immunosuppressed pa...

Arvind Singh

Thanks for your priced comments and the shared link. I acknowledge your valuable addition to the discussion.

Also, see the following useful link.

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1488/6067567

Please have a look on the below link:

https://publichealth.jhu.edu/2021/covid-19-outcomes-for-patients-on-immunosuppressive-drugs-on-par-with-non-immunosuppressed-patients#:~:text=People%20taking%20immunosuppressive%20drugs%20to,Bloomberg%20School%20of%20Public%20Health.

Please have a look on the below link:

https://www.frontiersin.org/articles/10.3389/fphar.2020.01333/full